Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW842470X · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Single dose 1 cohort | EXPERIMENTAL | Subjects with body surface area (BSA) disease involvement between 10 and 15% will be included. Subjects will receive either 100 milligrams (mg) GW842470X or placebo in a ratio of 2:1. |
| Repeat dose 1 cohort | EXPERIMENTAL | Subjects with BSA disease involvement between 10 and 15% will be included. Subjects will receive either 100-150 mg GW842470X or placebo in a ratio of 3:1 |
| Repeat dose 2 cohort | EXPERIMENTAL | Subjects with BSA disease involvement between 30 and 40% will be included. Subjects will receive either 300-400 mg GW842470X or placebo in a ratio of 3:1 |
| Repeat dose 3 cohort | EXPERIMENTAL | Subjects with BSA disease involvement \>=50% will be included. Subjects will receive either 500-1000 mg GW842470X or placebo in a ratio of 2:1 |
| Name | Type | Description |
|---|---|---|
| GW842470X cream | DRUG | - |
| GW842470X | DRUG | GW842470X will be available as a yellow smooth water-in-oil cream. |
| Placebo | DRUG | GW842470X matching placebo will be available as a yellow smooth water-in-oil cream. |
Inclusion criteria: * Moderate atopic dermatitis patients (IGA=3). * The disease involvement must be \>5% of body surface area. * Female patients of child-bearing potential must use an appropriate method of contraception. Exclusion criteria: * Patients with any active skin disease other than atop...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
GW842470X is an investigational small molecule being developed for the treatment of atopic dermatitis, also known as eczema. It is a topical cream intended for use in adult patients with moderate atopic dermatitis. The drug is currently in clinical development and has not been approved by regulatory authorities.
GW842470X is being developed by GSK plc, a global pharmaceutical company listed on the stock exchange under the ticker symbol GSK. GSK is conducting clinical trials to evaluate the safety and efficacy of this topical treatment for atopic dermatitis.
GW842470X is in Phase 2 clinical development. A Phase 2 trial has been completed, along with a Phase 1 study. The drug is investigational and has not received regulatory approval. It is being studied as a topical treatment for moderate atopic dermatitis in adults.
GW842470X has been studied in two completed clinical trials. NCT00354510 was a Phase 2 study of topical GW842470X in adults with moderate atopic dermatitis, enrolling 190 participants in Germany and the Netherlands. NCT00356642 was a Phase 1 study of single and ten-day repeat applications of GW842470X cream in patients with atopic dermatitis.
GW842470X is not FDA approved. It is an investigational drug that has completed Phase 1 and Phase 2 clinical trials for atopic dermatitis. The drug remains in clinical development and has not been authorized for marketing or use outside of clinical research settings.